华熙生物战略入股“中国核酸药物第一股”圣诺医药

Core Viewpoint - The strategic investment by Huaxi Biological in Shengnuo Pharmaceutical, known as "China's first nucleic acid drug stock," has significantly impacted the latter's stock price, which surged by 34.41% to HKD 4.57 per share as of September 8 [2]. Group 1: Investment Details - Shengnuo Pharmaceutical announced a discounted share placement of approximately 20%, aiming to raise HKD 208 million by issuing 17.35 million new shares at HKD 12 per share, which represents about 16.50% of the existing share capital [3][6]. - The investors in this placement include Huaxi Biological Technology (Hong Kong) Co., Ltd., and three other investors, with Huaxi Biological acquiring shares worth HKD 138 million, resulting in a 9.44% ownership stake [5][6]. Group 2: Financial Performance - Shengnuo Pharmaceutical has been in a loss-making state since its listing in 2021, with no product sales revenue generated as of June 30 this year [7]. - The company reported a total revenue of HKD 0.01 million for the first half of 2025, a decrease of 87.40% year-on-year, while total expenses were HKD 0.44 million, leading to an operating loss of HKD 0.43 million [8]. Group 3: Market Context - Huaxi Biological's investment is seen as a move to diversify its growth avenues beyond the beauty industry, especially as the company reported a 19.57% decline in revenue to HKD 2.26 billion and a 35.38% drop in net profit to HKD 221 million for the first half of 2025 [10][11]. - The company is also undergoing significant management changes and reforms to revitalize its operations, with 11 senior executives leaving the company recently [11].